

ANIMAL MODEL IN PRECLINICAL RESEARCH FOR DIURETICS

**R. K. Bhaghawan*, Dr. R. Manivannan, R. Rajamani, C. Sakthi, S. Santhapriyan,
T. Vijay**

Department of Pharmacology, Excel College of Pharmacy, Komarapalayam, Namakkal Dt.
Tamil Nadu, India.

Article Received on 15 Feb. 2026,
Article Revised on 05 March 2026,
Article Published on 16 March 2026,

<https://doi.org/10.5281/zenodo.19046445>

***Corresponding Author**

R. K. Bhaghawan

Department of Pharmacology, Excel
College of Pharmacy,
Komarapalayam, Namakkal Dt. Tamil
Nadu, India.



How to cite this Article: R. K. Bhaghawan*,
Dr. R. Manivannan, R. Rajamani, C. Sakthi, S.
Santhapriyan, T. Vijay (2026). Animal Model In
Preclinical Research For Diuretics. World
Journal of Pharmaceutical Research, 15(6),
1062-1070.

This work is licensed under Creative Commons
Attribution 4.0 International license.

ABSTRACT

Diuretics are essential pharmacological agents used in the management of hypertension, heart failure, renal disorders, and fluid overload conditions. Because these drugs directly influence renal physiology and electrolyte balance, their development demands rigorous preclinical investigation before clinical application. Animal models play a fundamental role in evaluating diuretic efficacy, safety, dose optimization, and mechanism of action under controlled experimental settings. Commonly employed models include saline-induced diuresis (Lipschitz test), metabolic cage studies, and disease-specific models such as hypertensive or renal impairment models. These systems enable precise measurement of urine volume, electrolyte excretion, osmolarity, renal biomarkers, and histopathological alterations. This review provides an integrated overview of renal physiology relevant to diuretics,

classification of diuretic agents, screening models, evaluation parameters, toxicity studies, statistical considerations, ethical guidelines, limitations, and recent alternative approaches in preclinical diuretic research.

KEYWORDS: Diuretics, Preclinical research, Animal models, Electrolytes, Renal physiology, Toxicity studies.


1. INTRODUCTION


Diuretics enhance urinary excretion of water and electrolytes, primarily sodium and chloride, thereby reducing extracellular fluid volume. These agents are widely prescribed in

cardiovascular, renal, and hepatic disorders. Given their direct action on renal tubular transport systems, even minor pharmacological alterations can significantly impact systemic fluid and electrolyte balance. Therefore, comprehensive preclinical evaluation is essential before human administration.

Preclinical research bridges laboratory discovery and clinical application. Whole-animal systems are particularly important in diuretic research because renal function is regulated through complex interactions involving glomerular filtration, tubular transport, neurohormonal pathways, and systemic hemodynamics. Animal models allow simultaneous assessment of these integrated processes.

2. RENAL PHYSIOLOGY RELEVANT TO DIURETIC RESEARCH





The nephron is the structural and functional unit of the kidney. Each kidney contains approximately one million nephrons, which coordinate filtration, reabsorption, secretion, and concentration of urine.

Key Functional Segments

- **Glomerulus:** Responsible for ultrafiltration of plasma.
- **Proximal Convoluted Tubule (PCT):** Reabsorbs the majority of filtered sodium and water.
- **Loop of Henle.**
 - Descending limb: permeable to water
 - Thick ascending limb: actively reabsorbs Na^+ , K^+ , and Cl^-
- **Distal Convoluted Tubule (DCT):** Fine regulation of sodium and calcium.
- **Collecting Duct:** Regulated by aldosterone and antidiuretic hormone.

Understanding these segments is essential because different classes of diuretics target specific transport mechanisms along the nephron.

3. CLASSIFICATION OF DIURETICS AND MECHANISMS OF ACTION

3.1 Loop Diuretics

Act on the thick ascending limb by inhibiting the $\text{Na}^+ - \text{K}^+ - 2\text{Cl}^-$ cotransporter. They produce powerful natriuresis and are used in acute pulmonary edema and severe fluid overload.

3.2 Thiazide Diuretics

Block the $\text{Na}^+ - \text{Cl}^-$ symporter in the distal convoluted tubule. They are commonly used as first-line therapy in hypertension.

3.3 Potassium-Sparing Diuretics

Act at the collecting duct either by antagonizing aldosterone receptors or blocking epithelial sodium channels.

They prevent potassium loss.

3.4 Carbonic Anhydrase Inhibitors

Reduce bicarbonate reabsorption in the proximal tubule and increase urine alkalinity.

3.5 Osmotic Diuretics


Increase tubular osmolarity and reduce water reabsorption throughout the nephron.

4. ROLE OF ANIMAL MODELS IN DIURETIC EVALUATION

Animal studies contribute to multiple phases of diuretic development.

1. **Primary Screening** – Identifying compounds with natriuretic activity.
 2. **Mechanistic Studies** – Determining transporter-specific effects.
 3. **Dose–Response Assessment** – Establishing effective and safe dose ranges.
 4. **Disease-Specific Evaluation** – Studying effects under hypertensive or renal-impaired conditions.
 5. **Safety Assessment** – Detecting nephrotoxicity and electrolyte imbalance.
- Rodents, particularly Wistar and Sprague-Dawley rats, are widely used due to reproducibility and well-characterized renal physiology.

5. SCREENING MODELS FOR DIURETIC ACTIVITY



5.1 Lipschitz Test

This is the standard experimental model for evaluating diuretic activity. Animals receive a uniform saline load followed by administration of the test compound. Urine is collected for a specified duration, typically 5–24 hours.

Measured parameters include.

- Urine volume
- Sodium, potassium, chloride levels
- Diuretic index
- Lipschitz value

5.2 Saline-Induced Diuresis

This method ensures standardized hydration and allows evaluation of natriuretic potential.

5.3 Disease-Induced Models

Hypertensive or renal-impaired animal models simulate clinical conditions and provide insight into therapeutic relevance.

6. EVALUATION PARAMETERS IN DIURETIC STUDIES

The effectiveness of a diuretic is assessed using quantitative and biochemical parameters.

- Total urine volume
- Electrolyte excretion (Na^+ , K^+ , Cl^-)
- Na^+/K^+ ratio

- Urine pH and osmolarity
- Serum creatinine and BUN
- Glomerular filtration rate

The diuretic index and Lipschitz value help compare test drugs with standard references.

7. DOSE–RESPONSE RELATIONSHIP

Dose–response studies determine drug potency, efficacy, and safety margin. Increasing doses typically produce a graded increase in urine output until a maximal effect (E_{max}) is reached.

Key parameters.

- ED50 (effective dose for 50% response)
- Therapeutic Index (LD_{50}/ED_{50})

These studies guide dose selection for subsequent toxicity and clinical phases.

8. TOXICITY STUDIES IN DIURETIC RESEARCH

Safety evaluation is critical due to the risk of electrolyte disturbances and renal injury.

Types of Toxicity Studies

- **Acute toxicity** – Single high dose evaluation
- **Sub-acute (28-day) studies**
- **Chronic toxicity studies**

Monitored parameters.

- Body weight changes
- Electrolyte imbalance
- Renal biomarkers
- Histopathological examination

Special emphasis is placed on hypokalemia, dehydration, and nephrotoxicity.

9. STATISTICAL CONSIDERATIONS

Proper statistical planning ensures scientific validity.

Common analyses include.

- Student's t-test
- One-way or Two-way ANOVA
- Regression analysis for dose–response curves

Results are typically expressed as Mean \pm SEM with significance set at $p < 0.05$.

10. ETHICAL CONSIDERATIONS

Ethical compliance is mandatory in animal experimentation. The 3Rs principle—Replacement, Reduction, and Refinement—guides responsible research practice. Institutional Animal Ethics Committee approval is required before experimentation.

Humane handling, monitoring of dehydration, and predefined endpoints are essential, particularly in diuretic studies where electrolyte imbalance may occur.

11. LIMITATIONS OF ANIMAL MODELS

Despite their importance, animal models have limitations:

- Species-specific differences in renal physiology
- Variability in drug metabolism
- Imperfect simulation of human diseases
- Translational challenges

Therefore, preclinical findings must be interpreted cautiously before extrapolation to human use.

12. RECENT ADVANCES AND ALTERNATIVE MODELS

Emerging technologies are complementing traditional animal studies:

- In vitro renal cell culture systems
- 3D kidney organoids
- Organ-on-a-chip platforms
- Computational pharmacokinetic modeling

These methods enhance translational relevance and reduce animal dependence, though complete replacement remains challenging.

CONCLUSION

Animal models remain indispensable in the preclinical evaluation of diuretics. They provide comprehensive insight into pharmacological activity, mechanism of action, safety profile, and dose optimization under physiologically integrated conditions. Although alternative technologies are advancing, whole-organism models continue to play a central role in bridging laboratory research and clinical therapeutics. Careful experimental design, ethical compliance, and rigorous statistical analysis are essential to ensure reliable and translatable outcomes in diuretic drug development.

REFERENCE

1. Alexander RT, Dimke H. Effect of diuretics on renal tubular transport of calcium and magnesium. *Am J Physiol Renal Physiol*, 2017; 312(6): F998-F1015. doi: 10.1152/ajprenal.00032.2017.
2. Mullens W, Damman K, Harjola VP, Mebazaa A, Brunner-La Rocca HP, Martens P, et al. The use of diuretics in heart failure with congestion — a position statement from the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail*, 2019; 21(2): 137-155. doi: 10.1002/ejhf.1369.
3. Felker GM, Ellison DH, Mullens W, Cox ZL, Testani JM. Diuretic therapy for patients with heart failure. *J Am Coll Cardiol*, 2020; 75(10): 1178-1195. doi: 10.1016/j.jacc.2019.12.059.
4. Arora T, Mehta AK, Joshi V, Mehta KD, Rathor N, Mediratta PK, Sharma KK. Substitute of animals in drug research: an approach towards fulfillment of 4R's. *Indian J Pharm Sci*, 2011; 73(1): 1-6. doi: 10.4103/0250-474X.89750.
5. Roush GC, Kaur R, Ernst ME. Diuretics: a review and update. *J Cardiovasc Pharmacol Ther*, 2014; 19(1): 5-13. doi: 10.1177/1074248413497257.
6. Ngamlai EV, Pradhan RB, Lalbiaknii PC, et al. Diuretic activity and chemical composition analysis of *Hedyotis scandens* extract in rat models. *J Ethnopharmacol*, 2024; 319(Pt 1): 117079.
7. Kau ST, Keddie JR, Andrews D. A method for screening diuretic agents in the rat. *J Pharmacol Methods*, 1984; 11(1): 67-75.
8. Hill TW, Randall PJ. A method for screening diuretic agents in the mouse: an investigation of sexual differences. *J Pharm Pharmacol*, 1976; 28(7): 552-4.
9. Sim MF, Hopcroft RH. Effects of various diuretic agents in the mouse. *J Pharm Pharmacol*, 1976; 28(8): 609-12.
10. Mariano LNB, Boeing T, da Silva RCVAF, et al. Preclinical evaluation of diuretic and saluretic effects of (-)-epicatechin and combination with standard diuretics. *Biomed Pharmacother*, 2018; 107: 520-5.
11. Xu Y, Zhang H, Li N, Ma W, Wang S, Sun J, et al. Preclinical pharmacokinetic studies of a novel diuretic inhibiting urea transporters. *Molecules*, 2022; 27(8): 2451.
12. Singh F, Sharma P, Jain V, Bhargava S. Phytochemical screening and evaluation of diuretic activity of *Setaria glauca*. *Int J Pharm Sci Drug Res*, 2022; 14(5): 589-94.
13. McClain RM, Dammers KD. Toxicologic evaluation of bumetanide, a potent diuretic agent. *J Clin Pharmacol*, 1981; 21(11): 543-54.

14. Wile D. Diuretics: a review. *Ann Clin Biochem*, 2012; 49(Pt 5): 419-31.
15. Koh SK, Jeong JW, Choi SI, et al. Pharmacokinetics and diuretic effect of furosemide in beagle dogs. *BMC Vet Res*, 2021; 17: 295.
16. Saleem H, Ahmad I, Gill MSA. Phytochemical screening and diuretic activity of *Euphorbia granulata* in rats. *Bangladesh J Pharmacol*, 2013; 10(3): 584-9.
17. Tadesse H, Engidawork E, et al. Diuretic activity of hydro-alcoholic extract of *Solanum lycopersicum* leaves in mice. *Sci Rep*, 2025; 15: 95628.
18. Dutta P, Layton AT. Magnesium and calcium transport along rat kidney: effects of diuretics. *Math Comput Appl*, 2024; 29(1): 13.
19. Naik BL, Meher CP. A comparative pharmacological study of diuretic drugs. *PharmaTutor*, 2016; 4(10): 10-20.
20. Kulkarni KM, Kondawar MS. Review on emerging trends and modifications of in vivo and in vitro screening techniques of diuretic activity. *Sys Rev Pharm*, 2022; 13(6): 399-404.